Literature DB >> 9484787

hSmad5 gene, a human hSmad family member: its full length cDNA, genomic structure, promoter region and mutation analysis in human tumors.

A Gemma1, K Hagiwara, F Vincent, Y Ke, A R Hancock, M Nagashima, W P Bennett, C C Harris.   

Abstract

hSmad (mothers against decapentaplegic)-related proteins are important messengers within the Transforming Growth Factor-beta1 (TGF-beta1) superfamily signal transduction pathways. To further characterize a member of this family, we obtained a full length cDNA of the human hSmad5 (hSmad5) gene by rapid amplification of cDNA ends (RACE) and then determined the genomic structure of the gene. There are eight exons and two alternative transcripts; the shorter transcript lacks exon 2. We identified the hSmad5 promoter region from a human genomic YAC clone by obtaining the nucleotide sequence extending 1235 base pairs upstream of the 5' end of the cDNA. We found a CpG island consistent with a promoter region, and we demonstrated promoter activity in a 1232 bp fragment located upstream of the transcription initiation site. To investigate the frequency of somatic hSmad5 mutations in human cancers, we designed intron-based primers to examine coding regions by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis. Neither homozygous deletions or point mutations were found in 40 primary gastric tumors and 51 cell lines derived from diverse types of human cancer including 20 cell lines resistant to the growth inhibitory effects of TGF-beta1. These results suggest that the hSmad5 gene is not commonly mutated and that other genetic alterations mediate the loss of TGF-beta1 responsiveness in human cancers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9484787     DOI: 10.1038/sj.onc.1201614

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  Internal ribosome entry site-mediated translation of Smad5 in vivo: requirement for a nuclear event.

Authors:  Kazuko Shiroki; Chieko Ohsawa; Natuki Sugi; Motoaki Wakiyama; Kin-ichiro Miura; Manabu Watanabe; Yutaka Suzuki; Sumio Sugano
Journal:  Nucleic Acids Res       Date:  2002-07-01       Impact factor: 16.971

2.  SMAD5 gene expression, rearrangements, copy number, and amplification at fragile site FRA5C in human hepatocellular carcinoma.

Authors:  Drazen B Zimonjic; Marian E Durkin; Catherine L Keck-Waggoner; Sang-Won Park; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  Neoplasia       Date:  2003 Sep-Oct       Impact factor: 5.715

3.  Identification and characterization of functional Smad8 and Smad4 homologues from Echinococcus granulosus.

Authors:  Chuanshan Zhang; Limin Wang; Hui Wang; Hongwei Pu; Le Yang; Jing Li; Junhua Wang; Guodong Lü; Xiaomei Lu; Wenbao Zhang; Dominique A Vuitton; Hao Wen; Renyong Lin
Journal:  Parasitol Res       Date:  2014-07-20       Impact factor: 2.289

4.  Conditional deletion of Smad1 and Smad5 in somatic cells of male and female gonads leads to metastatic tumor development in mice.

Authors:  Stephanie A Pangas; Xiaohui Li; Lieve Umans; An Zwijsen; Danny Huylebroeck; Carolina Gutierrez; Degang Wang; James F Martin; Soazik P Jamin; Richard R Behringer; Elizabeth J Robertson; Martin M Matzuk
Journal:  Mol Cell Biol       Date:  2007-10-29       Impact factor: 4.272

5.  Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database.

Authors:  Akihiko Gemma; Cai Li; Yuka Sugiyama; Kuniko Matsuda; Yoko Seike; Seiji Kosaihira; Yuji Minegishi; Rintaro Noro; Michiya Nara; Masahiro Seike; Akinobu Yoshimura; Aki Shionoya; Akiko Kawakami; Naoki Ogawa; Haruka Uesaka; Shoji Kudoh
Journal:  BMC Cancer       Date:  2006-06-30       Impact factor: 4.430

6.  Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.

Authors:  Rintaro Noro; Akihiko Gemma; Seiji Kosaihira; Yutaka Kokubo; Mingwei Chen; Masahiro Seike; Kiyoko Kataoka; Kuniko Matsuda; Tetsuya Okano; Yuji Minegishi; Akinobu Yoshimura; Shoji Kudoh
Journal:  BMC Cancer       Date:  2006-12-06       Impact factor: 4.430

7.  Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).

Authors:  Y Kokubo; A Gemma; R Noro; M Seike; K Kataoka; K Matsuda; T Okano; Y Minegishi; A Yoshimura; M Shibuya; S Kudoh
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.